271 related articles for article (PubMed ID: 32996763)
1. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
2. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
[TBL] [Abstract][Full Text] [Related]
3. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
4. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
5. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
6. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
[TBL] [Abstract][Full Text] [Related]
7. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with
Nguyen MQ; Kim DH; Shim HJ; Ta HKK; Vu TL; Nguyen TKO; Lim JC; Choe H
Mol Cells; 2023 Dec; 46(12):764-777. PubMed ID: 38052492
[TBL] [Abstract][Full Text] [Related]
8. Design of a modular immunotoxin connected by polyionic adapter peptides.
Kleinschmidt M; Rudolph R; Lilie H
J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
[TBL] [Abstract][Full Text] [Related]
9. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
Weldon JE; Pastan I
FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
[TBL] [Abstract][Full Text] [Related]
10. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
[TBL] [Abstract][Full Text] [Related]
11. Expression of VGRNb-PE immunotoxin in transplastomic lettuce (Lactuca sativa L.).
Mirzaee M; Jalali-Javaran M; Moieni A; Zeinali S; Behdani M
Plant Mol Biol; 2018 May; 97(1-2):103-112. PubMed ID: 29633168
[TBL] [Abstract][Full Text] [Related]
12. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
[TBL] [Abstract][Full Text] [Related]
13. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
14. [Studies of the expression, purification, renaturation and biologic activity of an anti-CEA immunotoxin].
Yang H; He D; Chao K; Lin Q; You S; Huang HL
Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):348-51. PubMed ID: 15971603
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A.
Gholami N; Cohan RA; Razavi A; Bigdeli R; Dashbolaghi A; Asgary V
J Cell Physiol; 2020 Apr; 235(4):3711-3720. PubMed ID: 31578716
[TBL] [Abstract][Full Text] [Related]
16. Creation and anti-cancer potency in HeLa cells of a novel chimeric toxin, HMGNCIDIN, composed of HMGN2 a-helical domain and PE38 KDEL domain III.
Xiong WB; Huang N; Feng Y; Wu Q; Wang BY
Chin Med J (Engl); 2008 Jan; 121(1):82-5. PubMed ID: 18208672
[No Abstract] [Full Text] [Related]
17. Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.
Amoozadeh S; Hemmati M; Farajollahi MM; Akbari N; Tarighi P
Cancer Invest; 2019; 37(10):546-557. PubMed ID: 31597492
[TBL] [Abstract][Full Text] [Related]
18. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
20. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
